DENEX, Renal Denervation Therapy, in Patients With Hypertension on no or 1-3 Antihypertensive Medications

Inclusion Criteria:

• Subject aged 19 to 75 years old
• Subject should maintain the 0 to 3 antihypertensive medications of different classes,ACE-I, ARB, beta blocker, CCB or diuretics, without change for at least 4 weeks ofrun-in period between primary screening and secondary screening and for at least 3months after the procedure
• Subject with 140 mmHg ≤ average office SBP < 180 mmHg and 90 mmHg ≤ office DBP < 120mmHg at primary and secondary screening
• Subject with 135 mmHg ≤ average daytime ambulatory SBP <170 mmHg and 85 mmHg ≤ averagedaytime ambulatory DBP < 105 mmHg at secondary screening after the run-in period forat least 4 weeks

Exclusion Criteria:

• Subject with the anatomical findings in kidney or renal artery which preclude renaldenervation
• Subject with type 1 diabetes mellitus or uncontrolled type 2 diabetes mellitus
• Subject with eGFR less than 40mL/min/1.73㎡
• Subject with a brachial circumference greater than 42 cm.
• Subject with secondary hypertension (except for sleep apnea patients)
• Subject with a medical history of cerebrovascular disease or severe cardiovasculardisease within 12 months prior to obtaining the consent or patients newly diagnosedwith such diseases before enrollment.
• Subject rehospitalized two or more times for hypertensive crisis within 12 monthsprior to obtaining consent or hospitalized for hypertensive crisis within three monthsprior to obtaining consent.
• Subject with chronic oxygen therapy or mechanical ventilation (except for sleep apnea)
• Subject with primary pulmonary hypertension